feed,title,long_url,short_url
Benzinga,Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment,https://benzinga.com/analyst-ratings/analyst-color/24/03/37943781/analysts-eye-summit-therapeutics-ivonescimab-as-potential-challenger-to-mercks-keyt,https://da.gd/u9tPk
